- 95.2k views
Dapagliflozin in patients with Chronic Kidney Disease
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
About the Speaker
Dr Satyanarayana Garre
Consultant Nephrologist, Apollo Hospitals, Hyderabad
Upcoming Case Discussions
A Case Based Approach to Acute Care Bronchoscopy: Skills for the Intensivists
A Case-Based Approach to Acute Care Bronchoscopy: Skills for the Intensivists focuses on enhancing practical bronchoscopy skills essential for managing critically ill patients. Through real-world case discussions, the session will cover key techniques, decision-making strategies, and troubleshooting during acute interventions. It aims to build confidence in handling airway emergencies, performing diagnostic procedures, and improving patient outcomes in the ICU. This interactive approach ensures intensivists are better prepared to apply bronchoscopy effectively in urgent care settings.
Gynaecologist’s Guide to Ovarian Cancer
Join us for a special webinar on World Ovarian Cancer Day, titled "Gynaecologist’s Guide to Ovarian Cancer." This expert-led session will delve into the latest advancements in early diagnosis, risk stratification, and evidence-based management of ovarian cancer. Tailored for gynecologists and healthcare professionals, the session will also explore real-world case discussions and multidisciplinary treatment approaches. Let’s come together to raise awareness and empower clinicians in the fight against this silent but deadly disease
Approach to severe hyperkalemia in ICU
Approach to Severe Hyperkalemia in the ICU focuses on rapid identification and targeted intervention to prevent life-threatening complications. The session outlines key steps including ECG monitoring, membrane stabilization with calcium gluconate, intracellular potassium shift using insulin-dextrose and beta-agonists, and potassium elimination via diuretics or dialysis. It emphasizes prioritizing reversible causes like renal failure or medication-induced hyperkalemia. Real-world ICU scenarios and evidence-based protocols will guide clinicians in managing this critical electrolyte emergency effectively.
Sleep Apnea and Daytime Fatigue
Sleep Disorder Breathing is a term for a group of conditions with abnormal breathing patterns during sleep. This affects everyday functioning and well being.There are few types of SDB which include upper airways resistance, hypopnea, apnea, catathrenia and heavy snoring. People suffering with SDB can have daytime symptoms that result in poor sleep also. There can also be sleepiness, depressed mood, irritability and cognitive dysfunction.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr Satyanarayana Garre's Talks on Assimilate
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.